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Abstract
Heritability of bone mineral density (BMD) varies across skeletal sites, reflecting different relative contributions of genetic
and environmental influences. To quantify the degree to which common genetic variants tag and environmental factors
influence BMD, at different sites, we estimated the genetic (rg) and residual (re) correlations between BMD measured at the
upper limbs (UL-BMD), lower limbs (LL-BMD) and skull (SK-BMD), using total-body DXA scans of ,4,890 participants
recruited by the Avon Longitudinal Study of Parents and their Children (ALSPAC). Point estimates of rg indicated that
appendicular sites have a greater proportion of shared genetic architecture (LL-/UL-BMD rg = 0.78) between them, than with
the skull (UL-/SK-BMD rg = 0.58 and LL-/SK-BMD rg = 0.43). Likewise, the residual correlation between BMD at appendicular
sites (re = 0.55) was higher than the residual correlation between SK-BMD and BMD at appendicular sites (re = 0.20–0.24). To
explore the basis for the observed differences in rg and re, genome-wide association meta-analyses were performed
(n,9,395), combining data from ALSPAC and the Generation R Study identifying 15 independent signals from 13 loci
associated at genome-wide significant level across different skeletal regions. Results suggested that previously identified
BMD-associated variants may exert site-specific effects (i.e. differ in the strength of their association and magnitude of effect
across different skeletal sites). In particular, variants at CPED1 exerted a larger influence on SK-BMD and UL-BMD when
compared to LL-BMD (P= 2.01610237), whilst variants at WNT16 influenced UL-BMD to a greater degree when compared to
SK- and LL-BMD (P= 2.31610214). In addition, we report a novel association between RIN3 (previously associated with
Paget’s disease) and LL-BMD (rs754388: b= 0.13, SE = 0.02, P= 1.4610210). Our results suggest that BMD at different skeletal
sites is under a mixture of shared and specific genetic and environmental influences. Allowing for these differences by
performing genome-wide association at different skeletal sites may help uncover new genetic influences on BMD.
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Introduction
Bone mineral density (BMD) at the femoral neck and lumbar
spine [as measured by dual-energy X-ray absorptiometry, (DXA)],
represents the primary diagnostic marker for osteoporosis as it
serves as a good predictor of bone strength and fracture risk in
adults [1]. Bone strength and fracture risk are influenced by: i)
bone acquisition in childhood, adolescence and young adulthood
ii) the subsequent maintenance of bone mass over the life course
and iii) the progressive loss of bone in later life [2,3]. Large-scale
genome-wide association studies (GWAS) using adult-BMD
measured at the femoral neck (FN) and lumbar spine (LS) have
successfully identified variants in 56 loci explaining 4–5% of the
phenotypic variance in adult-BMD [4–6]. However, it is possible
that the genetic variants influencing bone acquisition are different
from the ones involved in bone maintenance and bone loss across
the life course. Consequently, GWAS using paediatric-BMD
measurements have recently been performed with the goal of
identifying novel genetic variants primarily associated with bone
acquisition, whilst limiting the noise introduced by bone mainte-
nance and bone loss [7]. This approach has resulted in the
successful identification of novel BMD associated variants in the
WNT16 [7] and Osterix (SP7) loci [8] and it is highly likely that
more variants will be discovered as the sample size of these
paediatric studies increases.
In growing children, changes in bone area create artefacts
influencing the reproducibility, comparability and interpretation of
DXA measurements. For this reason, regions of interest (ROI)
containing larger bone areas [i.e. total-body, (TB)], which are less
prone to these artefacts, are preferred for paediatric evaluations of
bone health [9]. The skull region is generally excluded from TB-
DXA scans as its relative contribution to bone mass is
proportionally larger with respect to the rest of the body in
children, and its inclusion has been shown to make diagnostic
interpretation difficult [10]. However, from a locus discovery
perspective, it may be advantageous to partition TB-DXA further
into different regions, such as the upper and lower limbs and the
skull. This is important if genetic heterogeneity exists in terms of
loci differentially affecting BMD at different skeletal sites, or whose
effect is greater at some locations than in others. Considering that
environmental factors (i.e. mechanical loading) influence skeletal
sites differently, analysis of skull-BMD may be particularly
informative and even provide greater power to identify genetic
variants. This is the case given that the skull is less influenced by
mechanical loading than appendicular and other axial sites.
Further, the skull is frequently affected in monogenic conditions
involving the skeleton. For example, craniofacial abnormalities
such as thickening of the cranium and skull base are cardinal
features of van Buchems disease, Sclerosteosis and other sclerosing
bone dysplasias [11,12].
In the current study we examined whether genetic factors
influence bone mass accrual in a site-specific manner, by
performing regional analysis of TB-DXA scans, focussing on the
total-body less head (TBLH), lower limb (LL), upper limb (UL),
and skull (SK) regions. Using genome-wide complex trait analysis
(GCTA) on participants from the Avon Longitudinal Study of
Parents and their Children (ALSPAC), we assessed the proportion
of BMD variance explained by common genetic variants, across
each sub-region and additionally determined the shared genetic
and residual correlation between each sub-region. Subsequently,
we performed a genome-wide association (GWA) meta-analysis of
BMD at each skeletal site in the ALSPAC and Generation R
studies and went on to identify factors, which preferentially
influence one or more skeletal regions.
Results
Phenotypic correlation and genome-wide complex trait
analysis of BMD at different regions
Univariate GCTA analysis revealed that common genotyped
variants explained a greater proportion of the variance in SK-
BMD (vg = 0.51, SE= 0.07, P=2.0610
213) than LL- (vg = 0.40,
SE= 0.07, P=8.061029) or UL- (vg = 0.39, SE= 0.07,
P=2.061028) BMD. Higher phenotypic correlations were observed
when comparing LL- and UL-BMD than with SK-BMD (Table 1).
Similarly, bivariate GCTA analysis indicated that the strongest
genetic correlation was between BMD at the two appendicular
sites, whereas the genetic correlations involving SK-BMD were
more moderate. The residual correlation between the different sites
was in general smaller than the genetic correlation, and was higher
for BMD between the appendicular sites than for comparisons
involving the skull (Table 1). Highly similar magnitudes and
patterns of residual correlations were obtained for a sensitivity
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analysis in which BMD at all skeletal sites was corrected for age,
gender, weight and height (Table S1).
Genome wide meta-analysis of BMD across different
skeletal regions in ALSPAC and Generation R
Genome-wide association meta-analyses were performed on
TBLH-, LL-, UL- and SK-BMD, using regional BMD data
derived from ,9,395 TB-DXA scans. Detailed population
characteristics of the ALSPAC and Generation R cohorts are
summarised in Tables S2 and S3. Summary statistics from each
GWAS (after meta-analysis) indicated that negligible systematic
inflation of test statistics was observed (META lGC= 1.01–1.03).
In contrast, a marked deviation from the null was observed in the
tail of the distribution amongst the lowest observed P-values of the
meta-association analyses (Figure S1). SNPs in thirteen published
BMD-associated loci exceeded the genome-wide significance
(GWS) threshold for association (P#561028, Table 2). They
included variants which mapped close to, or within: WNT4
(1p36.12), WNT16/FAM3C/CPED1 (7q31.31) for all skeletal sites
measured, EYA4 (6q23.2), COLEC10/TNFRS11B (8q24.12),
LIN7C/LGR4 (11p14.1), PPP6R3/LRP5 (11q13.2) and
TNFRSF11A (18q21.33) for SK-BMD, CENPW/RSPO3
(6q22.32) for UL- and SK-BMD, TNFSF11 (13q14.11) and
GALNT3 (2q24.3) for UL- and TBLH-BMD. In addition, variants
proximal to or within FUBP3 (9q34.11) and KLHDC5/PTHLH
(12p11.22) were associated with TBLH- and LL-BMD. Further-
more, a novel signal (top SNP rs754388, 14q32.12), located within
Ras and Rab interactor 3 (RIN3) achieved genome-wide signifi-
cance after meta-analysis of LL-BMD (b=0.13, SE= 0.02,
P=1.4610210, Figure 1-I, Table 2) and TBLH-BMD (b=0.12,
SE= 0.02, P=3.061029, Table 2 and Figure S2). The full list of
all genome-wide significant SNPs and regional association plots for
each locus and skeletal site are presented in Supplementary Tables
S4, S5, S6, S7 and Figures S2, S3, S4, S5.
A followup of 66 independent SNPs at 58 loci, previously
associated with BMD [4,13], indicated that 31 loci showed
nominal evidence of association (P,0.05) with TBLH-BMD, 28
Author Summary
The heritability of bone mineral density (BMD) varies
across skeletal sites, reflecting different relative contribu-
tions of genetic and environmental influences. To inves-
tigate whether the genes underlying bone acquisition act
in a site-specific manner, we quantified the shared genetic
influences across axial and appendicular skeletal sites by
estimating the genetic and residual correlation of BMD at
the upper limb, lower limb and the skull. Our results
suggest that different skeletal sites as measured by total-
body Dual-Energy X-Ray Absorptiometry are to a certain
extent under distinct genetic and environmental influenc-
es. To further explore the basis for these differences,
genome-wide association meta-analyses were performed
to identify genetic loci that are preferentially associated
with one or more skeletal regions. Variants at 13 loci
(including RIN3, a novel BMD associated locus) reached
genome-wide significance and several displayed evidence
of differential association with BMD across the different
skeletal sites in particular CPED1 and WNT16. Our results
suggest that it may be advantageous to decompose the
total-body BMD measures and perform GWAS at separate
skeletal regions. By allowing for site-specific differences,
new genetic variants affecting BMD and future risk of
osteoporosis may be uncovered.
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with LL-BMD, 26 with UL-BMD and 26 with SK-BMD (versus
an expectation of 3.3. per phenotype) (Table S8). A similar
distribution of associations was also observed when a more
conservative threshold considering multiple hypothesis testing was
adopted that took into account the fact that 66 variants and four
phenotypes had been tested (i.e. a,1.961024). Using this
threshold nine variants showed evidence of association with
TBLH-BMD, seven with LL-BMD, six with UL-BMD and 10
with SK-BMD (versus an expectation of 0.1 per phenotype). We
note that in all cases where nominal significance was reached, the
direction of effect was consistent with previous studies.
To ensure that our results were robust to the possible effects of
population stratification and our choice of covariates, we
performed sensitivity analyses where we either restricted our
analysis to white European individuals only, or adjusted for the
same set of covariates across all analyses (i.e. age, gender, height,
and weight). Similar effect sizes and patterns of association were
observed for the top SNPs when adjusting BMD measures of all
four regions for age, gender, height and weight (Model 1a, Table
S9) and when limiting the GWAS meta-analysis to individuals of
European ancestry (Model 1b, Table S9). In both sensitivity
analyses, no additional loci reached the threshold of genome-wide
association (Figure S6 and S7).
Identification of novel BMD-associated signals
We assessed the presence of novel secondary association signals
at loci that contained genome-wide associated variants. Meta-
analysis of conditional association analyses resulted in the
attenuation of the majority of our top association signals (Table
S10, Figures S2, S3, S4, S5), indicating that these loci were not
independent from signals previously reported by other BMD
GWAS. However, the top signal for SK-BMD (rs2130604,
b=0.11, SE= 0.02, P=3.3610211), mapping near RSPO3, but
closest to CENPW (previously known as C6orf173, 6q22.32,
Figure 2A-I, Table 2) was only marginally attenuated after
conditional analysis (rs2130604, b=0.10, SE= 0.02,
P=7.161029, Figure 2A-II, Table S10). This suggests that
rs2130604 is largely independent from the previously reported
signal at RSPO3 (rs13204965, 6q22.32), which was identified in a
GWAS of individuals with extremely high or low BMD at the hip
[12] and later replicated in the second GEnetic Factors for
OSteoporosis Consortium (GEFOS-II) BMD meta-analysis [4].
This observation is further supported by low estimates of LD
(r2 = 0.14) between rs2130604 and rs13204965. Furthermore, the
secondary signal (after conditional analysis) reached the estimated
significance threshold of association after multiple testing correc-
tion (i.e. P#7.261025).
Interestingly, after conditioning rs4418209 (another SNP in the
same locus) on the published BMD-associated SNP rs13204965,
we observed a marked increase in its evidence of association
[(b=0.07, SE=0.02, P=1.161026) before and (b=0.09, SE=0.01,
P=7.9610210) after], (Figure 2A-II, Table S10). The rs4418209
variant maps closest to CENPW (6q22.32) and is in moderate LD
with the secondary independent signal (rs2130604, r2 = 0.43) and
in low LD with the published RSPO3 SNP (rs13204965, r2 = 0.12).
Whilst no other SNPs reached the threshold for declaring genome-
wide significance (P,561028), variants from three loci still yielded
suggestive evidence for association (P,161025) after conditional
analyses (Table S10 and Figures S2, S3, S4, S5). They included: i)
KLHDC5/PTHLH (rs4420311, 12p11.22) associated with TBLH-
(b=0.08, SE= 0.016, P=7.661027) and LL-BMD (b=0.08,
SE= 0.016, P=1.961026), ii) TNFSF11 (rs17536328 and
rs2148072, 13q14.11) associated with TBLH- (b=0.08,
SE= 0.015, P=5.661027) and UL-BMD (b=0.07, SE=0.015,
P=2.161026) respectively and iii) LIN7C/LGR4 [rs10160456,
11p14.1, (b=0.07, SE=0.015, P=7.861026)] with SK-BMD.
After conditional analysis, the secondary signal at LIN7C/LGR4
(i.e. rs10160456) mapped closest to CCDC34 and not to LIN7C, the
Figure 1. Regional association plot of the primary signal (rs754388) associate with lower limb-BMD at 14q32.12, in addition to a
comparison of the effect of rs754388 on bone mineral density at three different skeletal sites. For I and II: Circles show GWA meta-
analysis P-values and positions of SNPs found within the 14q32.12 locus. The top SNP, i.e. rs754388, is denoted by a diamond. Different colours
indicate varying degrees of pair-wise linkage disequilibrium (HapMap 2 CEPH) between the top SNP and all other SNPs. For II: The per-allele effect in
standard deviations (SD) (red dot) and the 95% confidence interval (error bar) of rs754388 for lower limb (LL), upper limb (UL) and skull (SK) BMD,
plotted with the strength of evidence against the null hypothesis of no association.
doi:10.1371/journal.pgen.1004423.g001
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gene closest to the primary signal. All these three loci might
represent novel secondary signals as the residual signal reached the
predicted locus specific threshold of association after multiple
testing correction (Table S10). However, we cannot exclude that
both associations (i.e. the primary and secondary signals) could
potentially arise from their association with one or more causal
variants, which could occur, on the same haplotype background.
For example, one such BMD-associated rare variant has recently
been identified in LGR4 in Icelandic populations although this
mutation appears specific to this population and therefore is
unlikely to account for the LIN7C/LGR4 signal we observe [14].
Comparison of the magnitude of the effect sizes of
genome-wide significant SNPs across skeletal-sites
The standardized per allele effect sizes (b) of all the top BMD-
associated SNPs were compared across three (SK-, UL-, and LL)
BMD regions to determine if they preferentially influenced one or
more skeletal sites (Table 3, Figure S8, S9, S10, S11). Effect sizes
of the following variants: rs2130604 (CENPW/RSPO3, 6q22.32),
rs3012465 (EYA4, 6q23.2), rs2450083 (COLEC10/TNFRS11B,
8q24.12), rs10835187 (LIN7C/LGR4, 11p14.1) and rs884205
(TNFRSF11A, 18q21.33) appeared to be largest for SK-BMD
when compared to UL- and LL-BMD (Figure S8). Furthermore,
differences in the magnitude of the effect were evident when
comparing independent genetic variants that occurred in close
proximity within a locus, as shown at the CENPW/RSPO3
(6q22.32) and WNT16/FAM3C/CPED1 (7q31.31) loci. Specifical-
ly, the independent signal (rs2130604, CENPW/RSPO3, 6q22.32)
associated with SK-BMD [b=0.11 (CI95: 0.08, 0.15)
P=3.3610211], was not strongly related to LL-BMD [b=0.02
(CI95: 20.02, 0.05), P=0.28], or UL-BMD [b=0.04, (CI95: 0.01,
0.07), P=0.02] (Table 3, Figure 2A-III). In contrast, a
neighbouring SNP (rs1262476) primarily associated with UL-
BMD appeared to influence BMD across all skeletal sites (Table 3,
Figure 2B-III). Differential patterns of association between SNPs at
neighbouring positions were also observed at the WNT16 locus
(Table 3, Figure 3A–C). Effect sizes were largest for UL-BMD at
rs2908004 (WNT16, 7q31.31, Table 3, Figure 3A-II) when
compared to SK- and LL-BMD. Interestingly, as compared to
LL-BMD, we observed consistently larger effect sizes for
rs13223036 and rs798943 (CPED1, previously known as C7orf58)
for SK- and UL-BMD, (Table 3, Figure 3B-II and 3C-II).
To formally determine whether the standardized regression
coefficients of each of the above-mentioned variants truly differed
across the skeletal sites, we fitted a multivariate normal likelihood
model to the raw data in ALSPAC and Generation R (see
Methods), and then meta-analysed the results using Fisher’s
method. Using a conservative threshold (i.e. a=561028), we
observed robust evidence indicating that i.e. rs13223036 and
rs798943, located at CPED1 exerted strong effects on UL and SK-
BMD, when compared to LL-BMD [P=2.01610237 and
P=4.44610236 (Table3)], whereas the variant rs2908004
Figure 2. Regional association plots of the top skull- and upper limb-BMD associated SNPs at the 6q22.32 locus before and after
conditioning on published SNP (rs13204965*) in addition to a comparison of the effect sizes of the top skull- (rs2130604) and
upper limb-BMD (rs1262476) associated SNP (before conditional analysis) on BMD at three different skeletal sites. For I and II: Circles
show GWA meta-analysis P-values and positions of SNPs found within each locus. Top SNPs are denoted by diamonds. Different colours indicate
varying degrees of pairwise linkage disequilibrium (HapMap 2 CEPH) between the top SNP and all other SNPs. Blue vertical shaded areas indicate the
position of rs2130604 (top SNP A-I) and rs1262476 (top SNP B-I) for each analysis. The red vertical shaded area represents the position of the
published SNP (rs13204965*). Rsids of relevant SNPs (blue dots) have been provided. For III: The per allele effect in SD (red dot) and 95% confidence
intervals (error bar) of each top SNP (before conditional analysis) for lower limb (LL), upper limb (UL) and skull (SK) BMD are plotted with their specific
strength of evidence against the null hypothesis of no association. Please note: RSPO3 is also found in the 6q.22.32 locus containing CENPW.
doi:10.1371/journal.pgen.1004423.g002
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Figure 3. Regional association plots of the top SNPs associated with total-body less head-, lower limb-, upper limb- and skull-BMD
at the 7q31.31 locus, in addition to a comparison of the effect size of the top site-specific SNP on BMD at the three different
skeletal sites. For I: Circles show GWA meta-analysis P-values and positions of SNPs found within the 7q31.31 locus. Top SNPs are denoted by
diamonds. Different colours indicate varying degrees of pair-wise linkage disequilibrium (HapMap 2 CEPH) between the top SNP and all other SNPs.
Blue vertical shaded areas indicate the position of rs7776725 (top SNP A-I) and rs2908004 (top SNP B-I) and rs798943 (top SNP C-I) for each analysis.
The red vertical shaded area represents the position of rs13223036 (top SNP D-I). For II: The per allele effect in SD (red dot) and the 95% confidence
interval (error bar) of the top SNP for lower limb (LL), upper limb (UL) and skull (SK) are plotted with their specific strength of evidence against the null
hypothesis of no association. Please note: FAM3C and CPED1 are also located at the 7q.31.31 locus containing WNT16.
doi:10.1371/journal.pgen.1004423.g003
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(WNT16) was strongly related to UL-BMD in comparison to BMD
at the other sites (P=2.31610214). Several variants at other loci
were also suggestive of some degree of skeletal site specificity
including EYA4 and LIN7C, although they did not formally meet
the criteria for statistical significance (Table 3, Figures S8, S9, S10,
S11).
Association of novel variants with hip and spine BMD
To elucidate if any of the novel primary and/or secondary
signals, identified during the course of this study, were nominally
associated with BMD in adults, we performed a lookup of these
variants in the publicly available results of the GEFOS-II meta-
analysis of hip and spine BMD (Table S11) [4]. The novel RIN3
variant (rs754388) was not associated with femoral neck
(PFN=0.87) and lumbar spine BMD (PLS=0.42). The G allele of
the EYA4 variant (rs3012465), associated with increased SK-BMD
(b=0.13, SE= 0.02, P=8.3610217), but surprisingly showed
nominal association with decreased BMD at both the hip
(P=7.161023) and spine (P=0.04). A followup of this variant in
a recent published GWAS of 4061 premenopausal women aged 20
to 45 revealed no evidence of association with FN-BMD (P=0.73)
[15].
A lookup of the secondary independent SNPs revealed no
evidence of a relationship between the TBLH- and LL-BMD-
associated KLHDC5/PTHLH variant (rs4420311) and associations
with hip or spine BMD (PFN=0.33 and PLS=0.45) in GEFOS-II.
Similarly no evidence of association was detected for the SK-
BMD-associated variant at CENPW/RSPO3 (rs2130604:
PFN=0.98 and PLS=0.40). Interestingly, the T allele of the
CENPW/RSPO3 variant (rs4418209), which was associated with
increased SK-BMD (b=0.07, SE=0.02, P=1.161026), appeared
to be nominally associated with decreased hip BMD
(P=5.061023) but not spine BMD (P=0.34). Further inspection
revealed that the T allele of rs4418209 was nominally associated
with decreased BMD at the TBLH (b=20.03, SE= 0.02,
P=1.761022), LL (b=20.04, SE= 0.02, P=6.561023) and
UL (b=20.04, SE= 0.02, P=8.261023). The T allele of
rs17536328 located within TNFSF11, associated with increased
TBLH-BMD, showed nominal evidence of association with
increased hip (P=0.04) but not spine BMD (P=0.87). In contrast,
the G allele of an independent TNFSF11 variant (rs2148072)
associated with increased UL-BMD was associated with decreased
spine BMD (P=0.05). In addition, the C allele LIN7C/LGR4
variant (rs10160456) associated with increased SK-BMD showed
weak evidence of association with increased hip (P=0.06) and
spine (P=0.03) BMD.
Bioinformatic analysis of RIN3
We fine mapped the RIN3 region by imputing common
and rare variants using a reference panel from the 1000
Genomes Project and identified a missense variant
(rs117068593) that was in strong linkage disequilibrium
(r2 = 0.96) with the top LL-and TBLH-BMD associated RIN3
variant (rs754388). The C allele of rs117068593 (EAF=0.82) was
associated with increased BMD of the lower limbs (b=0.13,
SE= 0.020, P=5.97610211) and total-body less head (b=0.12,
SE= 0.020, P=1.8761029). A search of the SIFT database [16]
revealed that the missense variant could negatively affect RIN3
functioning. This prediction was further supported by a search of
the Regulome database [17], which suggested that the missense
variant alters the binding of the following transcription factors:
EBF1, EGR1, SP1, NFKB1 and POLR2A, in lymphoblastic cell
lines.
RIN3 expression profiling
Evaluation of cis-expression quantitative trait loci (eQTLs) from
primary human osteoblasts using array-based gene expression
suggested that variants located within 1MB of RIN3 (i.e. including
variants tagging SLC24A4, LGMN, GOLGA5, CHGA and ITPK1)
were nominally associated with ITPK1 expression (P=0.04). This
observation failed to meet the level of significance after correction
for multiple testing. Examination of the temporal pattern of gene
expression across osteoblastogenesis, using mouse calvarial derived
cells, starting with the pre-osteoblast stage, through to mature
osteoblasts revealed that Rin3, Golga5 and Lgmn, and Iptk1 were
expressed in this cell type (Figure S12). In contrast, Slc24a4 and
Chga were not expressed at all in the pre- or mature osteoblast, as
determined by RNAseq. A further investigation of the expression
profiles of the aforementioned genes in human mesenchymal stem
cells [(hMSCs), differentiated into adipocytes and osteoblasts] and
peripheral blood monocytes [(PBMCs) differentiated into osteo-
clasts] indicated the following: SLC24A4 was not expressed in any
of these cell lines when differentiated, GOLGA5 had an interme-
diate expression level in both differentiating hMSCs and PBMCs
and LGMN was immediately upregulated upon differentiation into
adipocytes (8 fold), osteoblasts (5 fold) and osteoclasts [(5 fold),
Figure S13 and S14]. Moreover, we found that the expression of
RIN3 was 2-fold downregulated during the proliferative phase of
differentiating PBMCs into osteoclasts (Figure S13). Finally a
comparison of expression profiles across the RIN3 region of illiac
bone biopsies derived from 39 osteoporotic and 27 healthy
postmenopausal donors revealed one transcript (i.e. 220439_at,
originating from RIN3), that demonstrated reduced expression in
the osteoporotic group relative to the control group
[P=2.761023, (Table S13)].
Discussion
This study assessed whether regional analysis of skeletal sites
from TB-DXA could be used to estimate the extent to which
genetic and environmental factors influence bone mass accrual of
differentially loaded skeletal sites (skull, lower limbs, and upper
limbs). Point estimates indicated that common SNPs on a
commercially available genotyping array, explained a larger
proportion of the overall variance of SK-BMD, when compared
to BMD measured at the appendicular sites (i.e. lower and upper
limbs). These differences potentially reflect differential exposure of
each skeletal site to varying environmental stimuli that influence
BMD. Specifically the skull, as opposed to appendicular sites, is
less influenced by environmental factors, particularly those acting
through mechanical loading. To explore this result further, we
estimated the residual correlation (i.e. the proportion of environ-
mental and other sources of variation not tagged by SNPs on the
Illumina platform) across the different skeletal sites and found that
whilst the environmental (and other residual) factors influencing
the appendicular sites were moderately similar to each other, they
appeared to be appreciably different from the factors influencing
SK-BMD. Taken together, lower vg estimates, coupled with a high
residual correlation between the two appendicular sites, may
reflect the greater exposure of these sites to loading and muscular
stimulation, when compared to the skull.
Likewise, estimates of the genetic correlations indicated that the
appendicular limbs shared a more similar genetic architecture
when compared to the skull, possibly reflecting the composition of
bone at each skeletal site and the biological processes that govern
their growth and maintenance. For example, appendicular sites
consist of broadly equivalent proportions of cortical and trabecular
bone. The skull on the other hand is mainly comprised of flat
Genome-Wide Association Study of Whole-Body BMD
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bones, which consist primarily of cortical bone [18]. The
developmental processes also differ between long and flat bones,
with dermal bones such as the skull vault arising exclusively
through intramembranous bone formation, in contrast to long
bones, which form through endochondral bone formation
involving intermediary formation of cartilage [19].
To further explore the basis for the above-mentioned differences
in underlying genetic architecture, GWA meta-analyses of sub-
regional TB-DXA data were performed. These analyses helped
identifying genetic signals that were associated with one or more
skeletal region(s). When comparing the evidence of association for
all SNPs (identified in this effort) across each skeletal site, our
GWA meta-analyses echoed the findings of our GCTA results,
supporting the notion that although the underlying genetic
architecture influencing BMD appears to be largely similar, it
does vary according to skeletal site. The majority of the top SNPs
were nominally associated (P#0.05) with BMD across all skeletal
sites (i.e. SNPs at WNT4, WNT16, FAM3C, GALNT3, FUBP3,
KLHDC5/PTHLH, TNSF11, LIN7C/LGR4 and PPP6R3/LRP5).
In contrast, variants near or within CPED1, COLEC10/TNFRS11B
and EYA4 were strongly associated with UL- and SK-BMD, but
not LL-BMD. A further variant was identified within TNFRSF11A
that appeared to be solely related to SK-BMD. Most notably we
observed a novel association between rs754388 (located within
RIN3) and LL-/UL-BMD, but not SK-BMD. To the best of our
knowledge this is the first GWAS to report an association between
RIN3 and BMD. It seems likely that this association reflects a true
relationship with BMD as the same RIN3 signal (as determined by
conditional analysis) has previously been associated with an
increased risk of Paget’s Disease [i.e. rs10498635-C OR: 1.44,
95%-CI (1.29–1.60) P=3.610211] [20].
In an attempt to further understand how the genetic variation
surrounding RIN3 may influence BMD, we fine mapped RIN3 and
identified a missense variant (rs117068593) that was in high LD
with our LL-BMD associated SNP. Data mining of SIFT and
ENCODE databases suggested a functional role of the missense
variant that putatively affects binding of several transcription
factors in lymphoblastic cell lines. We further evaluated expression
quantitative trait locus (eQTL) data from primary human
osteoblasts using SNP data from HapMap (i.e. not including
rs117068593) and found no substantial evidence that our LL-
BMD associated SNPs located at 14q32.12 regulated the
expression of RIN3 or any of the genes located nearby. However,
differential patterns gene expression were detected when compar-
ing RIN3 expression profiles of osteoporotic and healthy individ-
uals. Further, we also observed differential expression during
osteoclast differentiation that was not present in osteoblast and
adipocyte differentiation processes. Collectively, the aforemen-
tioned observations appear to be in line with previous findings that
suggest that RIN3 could influence osteoclast activity, especially
when considering the prior association of RIN3 with Paget’s
Disease, a disease driven by osteoclast dysfunction and molecular
studies that indicate that RIN3 is involved in vesicular trafficking,
a process critical for bone resorption [20,21]. Further study is
however needed to elucidate the precise role of role of RIN3 in
bone metabolism.
To further understand the preferential associations of some
variants with different skeletal sites, we compared the standardized
effect sizes of all the genome-wide significant BMD-associated
variants, across each skeletal site using a formal multivariate
normal likelihood model. Variants at the CPED1 locus were
strongly associated with BMD at the skull and upper limb sites, but
not with LL-BMD. Similarly variants at WNT16 were more
strongly related to UL-BMD, than to BMD at the other sites.
Several other SNPs showed evidence for site specificity including
variants at the EYA4 and LIN7C loci that were very strongly
related to SK-BMD, although these variants did not surpass our
conservative criterion for declaring significant heterogeneity,
corroboration is needed from independent studies.
Conceivably, differences in the pattern of results across SNPs
may have arisen from an artefact of the measurement (i.e. where
sub-regional-specific associations reflect how accurately BMD is
measured at each skeletal site). However, if the latter were the
case, one would expect to observe a consistent pattern of results
across all loci (i.e. the strength of association should be greatest at
those sites measured more accurately). From our results, this is
clearly not the case as evidence of association is sometimes greatest
for the skull, whilst for other SNPs evidence is greatest for lower
and/or upper limbs. In terms of biological explanations, larger
effect sizes of genetic variants that influence SK-BMD possibly
reflect their preferential involvement in cortical as opposed to
trabecular bone metabolism and/or the involvement of intra-
membranous ossification vs. endochondral ossification [13].
Certain genetic factors also appeared to influence UL-BMD more
strongly than LL-BMD, or vice versa. Since the composition and
developmental origin of these two sites is broadly similar,
presumably, other explanations are responsible. It is reasonable
to think that genetic factors, which we identified, could be acting
to alter responses to stimuli that are themselves site-specific. For
example, adipose tissue has previously been reported to influence
cortical bone of the tibia in preference to the radius [22].
Quantitative SK-BMD measurements have traditionally been
ignored by genetic and epidemiological studies as they are thought
to be prone to errors such as dental augmentation. Despite these
concerns, a study conducted in premenopausal woman found a
high correlation between the upper half of the skull (i.e. cranial
vault) and total skull-BMD (r2 = 0.991, n = 91, Age range 19–30
years), with a mean difference of 20.004 g/cm2, suggesting that
these two measurements of bone mass are similar [23]. We found
that paediatric SK-BMD measures are well suited to GWAS, as
indicated by the very low P-values obtained at some of the known
BMD associated loci (10217 to 10228) despite our relatively small
sample size. This observation may reflect the fact that SK-BMD is
considerably less subject to environmental influences, such as those
acting through mechanical loading. In addition, genetic variants
associated with SK-BMD identified in this study may primarily
reflect molecular pathways involved in bone mass accrual and
growth, in contrast to variants identified from previous adult scans
which may be more strongly related to mechanisms involved in
bone maintenance and/or loss.
Almost all the loci we have identified in this study (i.e. with the
exception of SNPs in RIN3 and EYA4) have been associated with
BMD at either the hip or the lumbar spine previously. Variants
mapping to RIN3 have been implicated in Paget’s disease but this
is the first time the locus is associated with BMD, and interestingly,
the alleles associated with increased BMD are associated with
increased risk for the condition. This shows that performing
GWAS of BMD at sites other than at the femoral neck (FN-BMD)
or lumbar spine (LS-BMD) can be used to identify loci that exert
pleiotropic effects on bone. Potential advantages of examining
these additional sites from a locus discovery perspective are that (i)
genetic variants may exert stronger effects at these sites than at
FN-BMD/LS-BMD, and/or (ii) the genetic effects may be more
apparent at these sites because the effect of environmental noise is
minimized. For example, the P-values for skull BMD at several loci
(e.g. variants around CPED1, EYA4 and LIN7C) are many orders
of magnitude stronger than the corresponding P-values for TBLH-
BMD (see Table S8). Likewise variants in LIN7C were first
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discovered using a GWAS meta-analysis of lumbar spine that was
over five times the size of the present study, and even then only just
exceeded the threshold for genome-wide significance [4], whereas
in our study a variant at this locus has P,1610216 with SK-BMD.
Hence, GWAS of BMD at sites such as the skull could be used to
efficiently detect clinically relevant loci that might be more difficult
to discover in GWAS of the femoral neck and/or lumbar spine.
To further illustrate the value of SK-BMD, we draw attention to
rs3012465, a variant proximal to the eyes absent (EYA4) gene and
associated with increased SK-BMD. We show that the signal is
analogous to that previously associated with increased volumetric
cortical BMD of the tibia (i.e. C allele of rs271170: b=0.11,
P=2.7610212), based on a GWAS in ALSPAC and other young
adult cohorts [13], suggesting that both findings reflect the
relationship of the EYA4 locus with cortical bone. However, a
look-up in a separate cortical bone site (i.e. the femoral neck of the
hip), from a GWAS in older adults, revealed that the BMD-
increasing allele at the EYA4 locus was in fact associated with
lower BMD for both rs3012465 and rs271170 [4]. Taken together,
these findings may reflect an age dependent effect of EYA4
whereby EYA4 contributes to bone accrual in early life, yet maybe
influences bone loss in older adults. To test this hypothesis, we
followed up these EYA4 variants in a recent GWAS meta-analysis
of FN-BMD in 4061 pre-menopausal women aged 20–45 (as
described in Koller and colleagues [15]) and failed to find any
evidence of association with FN-BMD (P=0.73). These results
suggest that the discrepancy in results between GEFOS and the
present study is unlikely to be solely due to age, but rather is likely
to represent a real difference between skeletal sites.
In summary, our strategy of analysing regional paediatric DXA
measures of TB-BMD represents a novel approach to dissecting
the genetic architecture influencing bone mass accrual and growth
at different skeletal sites. Specifically, variants at 13 loci reached
genome-wide significance with BMD and several displayed
different degrees of association according to skeletal site. Further-
more, we report a novel association between a variant within RIN3
and LL-BMD and note its previous association with risk of Paget’s
disease. We additionally provide suggestive evidence of allelic
heterogeneity at the CENPW/RSPO3, KLHDC5/PTHLH and
LIN7C/LGR4 loci. In conclusion our results provide evidence that
different skeletal sites as measured by TB-DXA are to a certain
extent under distinct environmental and genetic influences.
Allowing for these differences may help to uncover new genetic
influences on BMD, particularly those examined in children as
involved in bone growth and accrual.
Materials and Methods
Subjects
ALSPAC. ALSPAC is a longitudinal population-based birth
cohort that recruited pregnant women residing in the former
county of Avon, UK, with an expected delivery date between 1st
April 1991 and 31st December 1992. This cohort has been
described in detail on the website (http://www.alspac.bris.ac.uk)
and elsewhere [24]. DXA, height and weight measurements were
performed on children who attended the 9 year old focus group
clinic [mean age of participant 9 (60.32 years)]. Ethical approval
was obtained from the ALSPAC Law and Ethics committee and
relevant local ethics committees, and all parents provided written
informed consent.
Generation R Study. The Generation R Study is a
prospective cohort study enrolling 9,778 pregnant women living
in Rotterdam with a delivery date from April 2002 until January
2006. Details of study design and data collection have been
described elsewhere [25]. DXA, height and weight measurements
were performed on children who visited the research centre whilst
being accompanied by their mothers at a mean age of 6 (60.5
years). All research aims and specific measurements taken during
the course of the Generation R Study have been approved by the
Medical Ethical Committee of the Erasmus Medical Center,
Rotterdam. All parents provided written informed consent.
Phenotypes
ALSPAC. TB-DXA scans were performed on all participants,
using a Lunar Prodigy scanner (Lunar Radiation Corp, Madison,
WI) with paediatric scanning software (GE Healthcare Bio-
Sciences Corp., Piscataway, NJ). DXA measures of BMD were
derived for the following regions of interest: TBLH-, UL-, LL- and
S. All DXA scans were subsequently reviewed by a trained
researcher, and re-analysed as necessary, to ensure that borders
between adjacent ROI’s were placed correctly by the automated
software. The coefficient of variation for TBLH-BMD measures
was 0.8%, based on the analysis of 122 children who had two
scans performed on the same day. Height was measured to the
nearest 0.1 cm using a Harpenden stadiometer (Holtain Ltd.,
Crymych, UK) and weight was measured to the nearest 50 g using
Tanita weighing scales (Tanita UK Ltd, Uxbridge).
Generation R Study. TB-BMD was measured in all partic-
ipants using a GE-Lunar iDXA scanner. Well-trained research
assistants obtained the DXA scans using the same device and
software (enCORE) following standard manufacturer protocols.
The same regions of interest as described for ALSPAC were
derived from TB-DXA scan. To ensure that the lines between
adjacent ROI’s were placed correctly by the automated software,
scans were evaluated twice, directly after the scanning and at a
later time point by a second well-trained research assistant. The
coefficient of variation for total TBLH-BMD measures was 0.23%,
based on duplicate scans of children that were performed on the
same day.
Genotyping and imputation
ALSPAC. A total of 9,912 subjects were genotyped using the
Illumina HumanHap550 quad genome-wide SNP genotyping
platform (Illumina Inc., San Diego, CA, USA) by 23andMe
subcontracting the Wellcome Trust Sanger Institute, Cambridge,
UK and the Laboratory Corporation of America (LabCorp
Holdings., Burlington, NC, USA). PLINK software (v1.07) was
used to carry out quality control measures [26]. Individuals were
excluded from further analysis on the basis of having incorrect
gender assignments, minimal or excessive heterozygosity (,0.320
and .0.345 for the Sanger data and ,0.310 and .0.330 for the
LabCorp data), disproportionate levels of individual missingness
(.3%), evidence of cryptic relatedness (.10% IBD) and being of
non-European ancestry (as detected by a multidimensional scaling
analysis seeded with HapMap 2 individuals). EIGENSTRAT
analysis revealed no additional obvious population stratification
and genome-wide analyses with other phenotypes indicate a low
lambda) [27]. SNPs with a minor allele frequency of,1% and call
rate of ,95% were removed. Furthermore, only SNPs that passed
an exact test of Hardy–Weinberg equilibrium (P.561027) were
considered for analysis. After quality control, 8,365 unrelated
individuals who were genotyped at 500,527 SNPs were available
for analysis. Known autosomal variants were imputed with
Markov Chain Haplotyping software (MACH 1.0.16) [28,29],
using CEPH individuals from phase II of the HapMap project
(hg18) as a reference set (release 22) [30]. The BMD associated
RIN3 locus was further imputed using the complete reference
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panel from the third phase of the 1000 Genomes Project (i.e.
March 2012) [31].
Generation R Study. Genotyping was performed using the
Illumina HumanHap 610 QUAD microarray using standard
manufacturer protocols. Stringent quality control of the genotype
and imputation process was performed in this study as previously
described [7]. Samples with gender discrepancy, excess of
heterozygosity, low genotype quality and sample replicates were
excluded from the analysis. A reference panel for imputation,
consisting of CEPH, YRI and CHB/JPT haplotypes was
constructed using data from phase 2 of the HapMap project
(hg18, release 22) [30]. A two-step imputation process was
performed using MACH for haplotype phasing and Minimac for
imputation [28,29]. A similar 1000 Genomes imputation strategy
(as described above for ALSPAC) was used to fine map the RIN3
locus.
Statistical methods
Choice of covariates. BMD as measured by DXA is strongly
influenced by weight, in part because weight is related to skeletal
size. BMD as assessed by DXA, does not correct for the thickness
(depth) of bone, therefore true (volumetric) bone mineral density is
often underestimated in smaller individuals and overestimated in
larger subjects. Weight is also thought to affect BMD by other
pathways such as increased skeletal loading, and possibly by other
metabolic influences. We reasoned that SK-BMD is likely to be
relatively unaffected by these other pathways, and so whereas
TBLH-, UL- and LL-BMD measures were adjusted for weight,
SK-BMD was adjusted for height.
Genome-wide complex trait analysis. Univariate restrict-
ed maximum likelihood (REML) genome-wide complex trait
analyses (GCTA) [32] were performed on $4,866 ALSPAC
subjects to estimate the proportion of additive genetic variance in
BMD at each site, explained by directly genotyped variants that
had a minor allele frequency $1%. Bivariate REML GCTA
analysis [33] was further used to estimate the pair-wise genetic and
residual correlations between BMD at each skeletal site. A cryptic
relatedness cut-off of 0.025 was applied in order to ensure that
distantly related individuals (i.e. n,444) were removed prior to the
analysis, thereby reducing the potential for bias (Figure S15).
GCTA analysis was not performed in the Generation R Study
given its multi-ethnic composition. Pearson Product Moment
Correlation was used to estimate the linear relationship between
standardised residuals of BMD after adjusting for age, gender, and
weight or height using the STATA statistical package [34].
Genome-wide association meta-analysis of BMD in
ALSPAC and Generation R. To identify genetic loci influenc-
ing variation in TBLH-, LL-, UL- and SK-BMD, we performed
GWAS meta-analyses combining 5,330 children (5,299 for SK-
BMD) from the ALSPAC cohort and 4,086 children from the
Generation R Study, who had DXA BMD measurements and
imputed GWAS data. Cohort specific GWAS analyses were
conducted in ALSPAC and Generation R using standardised
residuals derived from BMD measures after adjustment for age,
gender and weight for all skeletal sites except the skull, where
weight was substituted for height. The first 20 ancestry informative
principal components were additionally incorporated into the
Generation R model to control for population stratification, due to
the multi-ethnic nature of this cohort as described previously [7].
Genome-wide association analyses were performed using
MACH2QTL [29] as implemented in GRIMP [35], using linear
regression models based on an expected allelic dosage for SNPs,
adjusting for the above mentioned covariates where necessary. We
combined association data for ,2.5 million imputed autosomal
SNPs into an inverse variance fixed-effects meta-analysis, using
METAL and controlled for genomic inflation in each cohort [36].
P-values less than 561028 were considered genome-wide signif-
icant. Heterogeneity was evaluated using Cochran’s Q statistic and
was quantified by the I2 metric. Regional association plots from
our genome-wide association scans were generated using Locus-
zoom (v1.1) [37], using linkage-disequilibrium (LD) information
estimated from the HapMap 2 (hg18) CEPH reference dataset
[38]. All pair-wise LD estimates were obtained using SNAP
software in conjunction with the HapMap2Phase II (hg18) CEPH
reference dataset [39]. All remaining plots were generated in R
[40] using the ggplot2 software package [41].
Sensitivity analysis. In order to test the robustness of our
results to the choice of covariates at each site, we performed a
sensitivity analysis adjusting each region-specific BMD measure
for: age, gender, height and weight (i.e. Model 1a) and performing
GCTA and GWAS meta-analysis using the residuals. In order to
confirm that our results were not being driven by underlying
population substructure, we performed further GWAS meta-
analyses using the same residuals derived for Model 1a, except that
the analyses were restricted to individuals of European ancestry
(i.e. Model 1b).
Conditional meta-analysis. To identify novel secondary
BMD association signals (i.e. independent from those published),
at loci which reached genome-wide significance for each BMD
meta-analysis, we carried out conditional meta-analyses by
conditioning on all previously published BMD-associated variants
that mapped to between 1–2 Mb of the top locus specific SNP
[depending on the extend to LD, (Table S12)]. In the case of
rs7851693 (FUBP3), not present in the Generation R dataset,
conditional analysis was performed using a proxy SNP (i.e.
rs7030440), which was in high LD (r2.0.96) with the missing
BMD associated variant. For RIN3, there were no BMD associated
loci previously published, thus for that locus we conditioned on the
top SNP. After conditional analysis, locus specific significance
correction thresholds (for multiple testing of SNPs which are in
linkage disequilibrium with each other) were calculated using the
Single Nucleotide Polymorphism Spectral Decomposition
(SNPSpD) software package [42]. Locus specific regions used for
SNPSpD were defined as the region proximal (1–2 Mb) to each
locus specific signal. The presence of independent secondary
association signals was confirmed in situations where the residual
signal (after conditional meta-analysis) reached the locus specific
threshold corrected for multiple testing.
Comparison of the magnitude of the effect sizes of
genome-wide significant SNPs across skeletal-sites. As
we were interested in whether the genetic variants exerted greater
influence on BMD at a particular site, it would be misleading to
directly compare standardized regression coefficients from the
meta-analysis by e.g. simple Z test, since the summary statistics
were derived from correlated measures on the same individuals
and are therefore not independent. In addition, because we are
only testing variants that have already met the criterion for
genome-wide significance (and were therefore selected on the basis
of having an extreme regression coefficient at a particular site), it is
not appropriate to compare the regression coefficients from
different sites using an uncorrected type I error level of a=0.05.
To address both these considerations, we fitted a multivariate
normal model to the standardized BMD scores at each site by
maximum likelihood using the software package Mx [43]. We
fitted a model where the standardized regression coefficients for
each site (SK-BMD, LL-BMD, UL-BMD) were constrained to be
equal, and then another model in which the regression coefficient
most different from the other two was allowed to vary). Twice the
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difference in log-likelihood between these models is distributed as a
chi-square statistic with one degree of freedom. We analysed each
cohort separately using this method and then combined the results
using Fisher’s product of P-values evaluating statistical significance
against a conservative threshold of a=561028 (i.e. as if we had
performed the comparison genome-wide, not just post-hoc on the
significant sites).
Functional analysis of RIN3
In an attempt to identify a potential functional or regulatory
mechanism underlying the association between RIN3 and BMD, a
range of bio-informatic and functional analyses were performed.
These included: fine mapping the RIN3 locus, data mining
Regulome [17] and SIFT [16] databases and performing eQTL
analysis on primary human osteoblasts. The expression profiles of
RIN3 and neighboring genes: SLC2484, LGMN, GOLGA5, CHGA
and ITPK1 were also investigated in bone biopsies of healthy and
osteoporotic women, in addition to murine and human cell lines
that were differentiated into osteoblasts and/or osteoclasts.
Methods specific to each analysis are described below.
Human primary osteoblasts. Expression profiling of un-
treated primary human osteoblasts, obtained from 113 (51 female
and 62 male) unrelated Swedish donors, was performed using the
Illumina HumRef-8 BeadChips in accordance with the manufac-
turer’s instructions. Up to 3 biological replicates were analysed per
sample. Genotyping for genotype-expression association was
performed using the Illumina HapMap 550 k Duo chip.
Individuals with low genotyping rate and SNPs showing significant
deviation from Hardy-Weinberg equilibrium (P,0.05) were
excluded. Similarly, low frequency (MAF,0.05) SNPs and SNPs
with high rates of missing data were excluded. Genotypes from
samples that passed quality control (n = 103) were imputed for all
SNPs (n = 478,805) oriented to the positive strand from phased
autosomal chromosomes of HapMap Phase 2 CEPH panel
(release 22, build 36) using MACH 1.0. A RSQR cut-off of ,
0.3 was used to remove poorly imputed markers. Association of
imputed genotypes using estimated genotype probabilities with
nearby expression traits (defined as 61 Mb window flanking
RIN3) was performed using a linear regression model implemented
in the MACH2QTL software with sex and age as covariates.
Detailed methods pertaining to the data generation and analysis
are described elsewhere [44,45].
Human illiac bone biopsies. Gene expression profiles were
generated from iliac bone biopsies donated by healthy control
(n = 27), osteopenic (n = 18) and osteoporotic (n = 39) postmeno-
pausal Norwegian women. The affection status of each individual
was determined by BMD measurements of the total hip or lumbar
spine (L1–L4 vertebrae). Individuals with a T-score less than 22.5
and with at least one low trauma fracture were deemed
osteoporotic, whilst individuals with a T-score .21 were deemed
healthy. Expression profiling was performed using an Affymetrix
HG U133 2.0 plus array. The Affymetrix Cel files were imported
into Partek Genomics Suite (Partek Inc., St Louis, MO, USA), and
normalized using the RMA (Robust Multichip Average) algo-
rithm. Gene expression patterns were further adjusted, as reported
by Jemtland and colleagues [46], for batch effects and differing
synthesis times. The gene expression profiles of all transcripts
located 6250 kb of the top LL-BMD associated RIN3 SNP (i.e.
rs754388) were compared between the osteoperotic and control
group. Note: the intermediate osteopenic group was excluded from
this analysis.
Murine pre-osteoblasts. All procedures and use of mice for
the neonatal osteoblast expression studies were approved by the
Jackson Laboratory Animal Care and Use Committee (ACUC), in
accordance with NIH guidelines for the care and use of laboratory
animals. Pre-osteoblast-like cells were isolated from neonatal
calvaria from C57BL/6J mice expressing cyan florescent protein
(CFP) under the control of the Col3.6 promoter (pOBCol3.6CFP),
using standard techniques [47]. Cells were cultured for 4 days in
growth media [DMEM containing 10% fetal bovine serum (FBS)
and 16 penicillin/streptomycin], and thereafter removed from
culture and subjected to fluorescence-activated cell sorting (FACS)
based on the presence/absence of CFP expression. Cells
expressing CFP, and therefore considered pre-osteoblasts, were
plated at a density of 16104 cells per cm2, differentiated into
osteoblasts using standard methods (aMEM containing 50 mg/ml
Ascorbic Acid, 4 mM b-glycerol phosphate, 10% FBS and 16
penicillin/streptomycin). RNA was collected at 9 time points post
differentiation. mRNA profiles for triplicate samples for each time
point were generated by Next Generation High throughput RNA
sequencing (RNAseq), using an Illumina HiSeq 2000. The
alignments for abundance estimation of transcripts was conducted
using Bowtie version 0.12.9 [48] using the NCBIm37 transcrip-
tome as the reference genome. Expression level per gene was
calculated using RSEM version 1.2.0 using the following
parameters: –fragment-length-mean 280 and –fragment-length-
sd 50 [49] and expression level for each sample was normalized
relative to the per sample upper quartile [50]. This data has been
submitted to the gene expression omnibus (Accession Number:
GSE54461).
Human mesenchymal stem cells and peripheral blood
mononuclear cells. Human bone marrow derived mesenchy-
mal stem cells [(hMSC), Lonza Group Ltd., Basel, Switzerland]
were seeded in 12-well plates (56103 cells per cm2) and
differentiated into osteoblasts (using a-Mem pH 7.5, 10% heat
inactivated foetal calf serum (FCS), 100 nM Dexamethasone and
10 mM b-glycerophosphate) or adipocytes (using a-MEM pH 7.5,
10% heat inactivated FCS, 100 nM dexamethasone, 500 mM
IBMX and 60 mM Indomethacin). Total RNA was isolated
(triplicates) using Trizol (Life Technologies, Carlsbad, CA, USA)
twice a week during differentiation until the 25 day of culture.
Human peripheral blood mononuclear cells (PBMCs) were
retrieved from buffy coats using Ficoll and seeded in 12-well
plates (1.36105 cells per cm2). Monocytes were allowed to attach
for 4 hours and non-adherent cells were removed by careful
washing. In the next three days, cells were grown in a-Mem
pH 7.5, containing 15% heat-inactivated serum and 25 ng/ml
macrophage colony stimulating factor [(M-CSF), R&D Systems
Inc., Minneapolis, MN, USA] to stimulate proliferation of the
monocytes. After 3 days, media was replaced with a-Mem pH 7.5
containing 15% heat inactivated serum, 25 ng/ml M-CSF and
30 ng/ml RANKL (Peprotech Inc., Rocky Hill, NJ, USA) to
initiate osteoclastogenesis. Total-RNA was isolated twice a week
using Trizol until the 21st day of culture. Amplification of total-
RNA, Illumina microarray hybridization, data extraction and
normalization were performed as previously described [51].
Supporting Information
Figure S1 Genome-wide association meta-analysis of age-,
gender-, height- or weight-adjusted BMD measured at four
different skeletal sites. Manhattan and Q-Q plots derived from
the genome-wide association meta-analysis of BMD measures of
the total-body less head (TBLH), lower limb (LL), upper limb (UL)
and skull (SK). The names of the closest genes relative to the each
locus specific top SNP are indicated in blue. Q-Q plots show the
inflation of the test statistics (lMETA) of each genome-wide
association meta-analysis. *Please note that PTHLH is also located
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at the 12p11.22 locus containing KLHDC5, RSPO3 is also located
at the 6q.22.32 locus containing CENPW, FAM3C and CPED1 are
also located at the 7q.31.31 locus containingWNT16, TNFRSF11B
is also located at the 8q.24.12 locus containing COLEC10, LGR4 is
also located at the 11p14.1 locus containing LIN7C and LRP5 is
also located at the 11q13.2 locus containing PPP6R3.
(TIF)
Figure S2 Regional association plots for all loci which reached
genome-wide significance for TBLH-BMD before and after
conditioning on known BMD associated SNPs. Circles show
GWA meta-analysis P-values and positions of SNPs found within
each locus. The top SNP are denoted by diamonds. Different
colours indicate varying degrees of pair wise linkage disequilibrium
estimates between the top SNP and all other SNPs. *Please note
that PTHLH is also located at the 12p11.22 locus containing
KLHDC5, RSPO3 is also located at the 6q.22.32 locus containing
CENPW, FAM3C and CPED1 are also located at the 7q.31.31 locus
containing WNT16, TNFRSF11B is also located at the 8q.24.12
locus containing COLEC10, LGR4 is also located at the 11p14.1
locus containing LIN7C and LRP5 is also located at the 11q13.2
locus containing PPP6R3.
(TIF)
Figure S3 Regional association plots for all loci which reached
genome-wide significance for LL-BMD before and after condi-
tioning on known BMD associated SNPs. Circles show GWA
meta-analysis P-values and positions of SNPs found within each
locus. The top SNP are denoted by diamonds. Different colours
indicate varying degrees of pair wise linkage disequilibrium
estimates between the top SNP and all other SNPs. *Please note
that PTHLH is also located at the 12p11.22 locus containing
KLHDC5, RSPO3 is also located at the 6q.22.32 locus containing
CENPW, FAM3C and CPED1 are also located at the 7q.31.31 locus
containing WNT16, TNFRSF11B is also located at the 8q.24.12
locus containing COLEC10, LGR4 is also located at the 11p14.1
locus containing LIN7C and LRP5 is also located at the 11q13.2
locus containing PPP6R3.
(TIF)
Figure S4 Regional association plots for all loci which reached
genome-wide significance for UL-BMD before and after condi-
tioning on known BMD associated SNPs. Circles show GWA
meta-analysis P-values and positions of SNPs found within each
locus. The top SNP are denoted by diamonds. Different colours
indicate varying degrees of pair wise linkage disequilibrium
estimates between the top SNP and all other SNPs. *Please note
that PTHLH is also located at the 12p11.22 locus containing
KLHDC5, RSPO3 is also located at the 6q.22.32 locus containing
CENPW, FAM3C and CPED1 are also located at the 7q.31.31 locus
containing WNT16, TNFRSF11B is also located at the 8q.24.12
locus containing COLEC10, LGR4 is also located at the 11p14.1
locus containing LIN7C and LRP5 is also located at the 11q13.2
locus containing PPP6R3.
(TIF)
Figure S5 Regional association plots for all loci which reached
genome-wide significance for SK-BMD before and after condi-
tioning on known BMD associated SNPs. Circles show GWA
meta-analysis P-values and positions of SNPs found within each
locus. The top SNP are denoted by diamonds. Different colours
indicate varying degrees of pair wise linkage disequilibrium
estimates between the top SNP and all other SNPs.*Please note
that PTHLH is also located at the 12p11.22 locus containing
KLHDC5, RSPO3 is also located at the 6q.22.32 locus containing
CENPW, FAM3C and CPED1 are also located at the 7q.31.31 locus
containing WNT16, TNFRSF11B is also located at the 8q.24.12
locus containing COLEC10, LGR4 is also located at the 11p14.1
locus containing LIN7C and LRP5 is also located at the 11q13.2
locus containing PPP6R3.
(TIF)
Figure S6 Genome-wide association meta-analysis of age-,
gender-, height- and weight-adjusted BMD measured at four
different skeletal sites. Manhattan and Q-Q plots derived from the
genome-wide association meta-analysis of BMD measures of the
total-body less head (TBLH), lower limb (LL), upper limb (UL)
and skull (SK). The names of the closest genes relative to the each
locus specific top SNP are indicated in blue. Q-Q plots show the
inflation of the test statistics (lMETA) of each genome-wide
association meta-analysis. *Please note that PTHLH is also located
at the 12p11.22 locus containing KLHDC5, RSPO3 is also located
at the 6q.22.32 locus containing CENPW, FAM3C and CPED1 are
also located at the 7q.31.31 locus containingWNT16, TNFRSF11B
is also located at the 8q.24.12 locus containing COLEC10, LGR4 is
also located at the 11p14.1 locus containing LIN7C and LRP5 is
also located at the 11q13.2 locus containing PPP6R3.
(TIF)
Figure S7 Genome-wide association meta-analysis of age-,
gender-, height- and weight-adjusted BMD measured at four
different skeletal sites in individuals of European ancestry.
Manhattan and Q-Q plots derived from the genome-wide
association meta-analysis of BMD measures of the total-body less
head (TBLH), lower limb (LL), upper limb (UL) and skull (SK).
The names of the closest genes relative to the each locus specific
top SNP are indicated in blue. Q-Q plots show the inflation of the
test statistics (lMETA) of each genome-wide association meta-
analysis. *Please note that PTHLH is also located at the 12p11.22
locus containing KLHDC5, RSPO3 is also located at the 6q.22.32
locus containing CENPW, FAM3C and CPED1 are also located at
the 7q.31.31 locus containing WNT16, TNFRSF11B is also located
at the 8q.24.12 locus containing COLEC10, LGR4 is also located at
the 11p14.1 locus containing LIN7C and LRP5 is also located at
the 11q13.2 locus containing PPP6R3.
(TIF)
Figure S8 Comparison of effect sizes of the top SK-BMD
associated variants across each skeletal site. The per allele effect in
SD (red dot) and 95% confidence interval (error bar) of the top
SNP associated with BMD measurements of the lower limb (LL),
upper limb (UL) and skull (SK) are plotted with their specific
strength of association. *Please note that PTHLH is also located at
the 12p11.22 locus containing KLHDC5, RSPO3 is also located at
the 6q.22.32 locus containing CENPW, FAM3C and CPED1 are
also located at the 7q.31.31 locus containingWNT16, TNFRSF11B
is also located at the 8q.24.12 locus containing COLEC10, LGR4 is
also located at the 11p14.1 locus containing LIN7C and LRP5 is
also located at the 11q13.2 locus containing PPP6R3.
(TIF)
Figure S9 Comparison of effect sizes of the top UL-BMD
associated variants across each skeletal site. The per allele effect in
SD (red dot) and 95% confidence interval (error bar) of the top
SNP associated with BMD measurements of the lower limb (LL),
upper limb (UL) and skull (SK) are plotted with their specific
strength of association. *Please note that PTHLH is also located at
the 12p11.22 locus containing KLHDC5, RSPO3 is also located at
the 6q.22.32 locus containing CENPW, FAM3C and CPED1 are
also located at the 7q.31.31 locus containingWNT16, TNFRSF11B
is also located at the 8q.24.12 locus containing COLEC10, LGR4 is
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also located at the 11p14.1 locus containing LIN7C and LRP5 is
also located at the 11q13.2 locus containing PPP6R3.
(TIF)
Figure S10 Comparison of effect sizes of the top LL-BMD
associated variants across each skeletal site. The per allele effect in
SD (red dot) and 95% confidence interval (error bar) of the top
SNP associated with BMD measurements of the lower limb (LL),
upper limb (UL) and skull (SK) are plotted with their specific
strength of association. *Please note that PTHLH is also located at
the 12p11.22 locus containing KLHDC5, RSPO3 is also located at
the 6q.22.32 locus containing CENPW, FAM3C and CPED1 are
also located at the 7q.31.31 locus containingWNT16, TNFRSF11B
is also located at the 8q.24.12 locus containing COLEC10, LGR4 is
also located at the 11p14.1 locus containing LIN7C and LRP5 is
also located at the 11q13.2 locus containing PPP6R3.
(TIF)
Figure S11 Comparison of effect sizes of the top TBLH-BMD
associated variants across each skeletal site. The per allele effect in
SD (red dot) and 95% confidence interval (error bar) of the top
SNP associated with BMD measurements of the lower limb (LL),
upper limb (UL) and skull (SK) are plotted with their specific
strength of association. *Please note that PTHLH is also located at
the 12p11.22 locus containing KLHDC5, RSPO3 is also located at
the 6q.22.32 locus containing CENPW, FAM3C and CPED1 are
also located at the 7q.31.31 locus containingWNT16, TNFRSF11B
is also located at the 8q.24.12 locus containing COLEC10, LGR4 is
also located at the 11p14.1 locus containing LIN7C and LRP5 is
also located at the 11q13.2 locus containing PPP6R3.
(TIF)
Figure S12 Gene expression profiles of Rin3, Golga5 Lgmn, and
Itpk1 measured throughout the osteoblast maturation process in
cells extracted from mouse calvariae, as measured by RNAseq.
Samples for expression purposes were collected every other day for
18 days, starting 2 days after the cells were first exposed to an
osteoblast differentiation cocktail. Relative transcript abundance is
expressed as the number of query transcripts per million unique
transcripts (transcripts per million), after normalizing to the upper
quartile. A local weighted scatterplot smoothing curve was plotted
to help with visualizing the expression pattern. Note: Slc24a4 and
Chgm were not expressed in this cell type and have not been
included in the figure.
(TIF)
Figure S13 Gene expression profile of RIN3, LGMN, GOLGA5
and ITPK1 measured in osteoclast differentiating human PBMCs.
Relative transcript abundance is expressed as Log2 normalized
intensities. Each value is an average of 3 independent measure-
ments and a standard deviation.
(TIF)
Figure S14 Gene expression profile of RIN3, LGMN, GOLGA5
and ITPK1 measured in adipogenic and osteogenic differentiating
hMSCs. Relative transcript abundance is expressed as Log2
normalized intensities. RIN3 expression levels in differentiating
hMSC are absent because the intensities were at background level.
Each value is an average of 3 independent measurements and a
standard deviation.
(TIF)
Figure S15 Flow diagram and overview of the analysis strategy
used in this study. For ALSPAC, a total of 9,912 subjects were
genotyped by Wellcome Trust Sanger Institute, Cambridge and
the Laboratory Corporation of America. Individuals were
excluded from further analysis using several quality control (QC)
criteria (See methods). After merging and further QC, 8,365
unrelated subjects [identity by decent (IBD) ,10% and of
European ancestry] were available for GWAS analysis. Total-
body DXA scans were performed on 7725 subjects that attended
the Focus 9 clinic. Of these a total of 6540 passed DXA QC. For
total body (TB), lower limb- (LL) and upper limb (UL) GWAS
analysis 5,330 subjects had high quality bone mineral density
(BMD) and genetic data, whereas 5,229 subjects were available for
skull (S). For GCTA analysis, we employed a strict threshold of
genome-wide identity by state .2.5% and resulting in the
exclusion of additional individuals on the basis of cryptic
relatedness. 4,891 (TB-, LL- and UL-BMD) and 4,866 (S-BMD)
subjects were available for GCTA analysis. For Generation R
study a total of 5,908 subjects were genotyped by the Erasmus
Medical Centre. Following QC 5,756 individuals had high quality
genotyping data. Total-body DXA scans were performed on 6,509
subjects, of these a total of 6,490 passed DXA QC. High quality
BMD and genetic data was available for 4,086 subjects. Of these
2,177 subjects were of Dutch-European decent. Two GWAS
meta-analysis strategies were performed for each site. The first
strategy involved all the subjects in the ALSPAC and the
Generation-R studies. The second approach involved all the
ALSPAC subjects, but was restricted to Generation R subjects
who were of European descent. The number of subjects (n)
involved in each step of the analysis is indicated. =Number of
subjects that had S-BMD measurements that passed QC.
W=Number of Generation R subjects that were of Dutch-
European descent.
(TIF)
Table S1 Bivariate GCTA estimates of the genetic and residual
correlations of age-, gender-, height- and weight-corrected bone
mineral density measurements of the total-body less head, lower
limb, upper limb and skull. (TBLH)= total-body less head, (LL-
BMD)= lower limb BMD, (UL-BMD)= upper limb BMD, (SK-
BMD)= skull BMD, rg = genetic correlation between trait 1 and
trait 2. re = residual correlation between trait 1 and trait 2. All
traits were adjusted for age, gender and height and weight. P-refers
to the P-value for the likelihood ratio test of whether rg = 0.
Phenotypic correlations (rp) were as follows: SK-BMD/TBLH-
BMD (rp = 0.44, SE= 0.012, P,0.001), SK-BMD/LL-BMD
(rp = 0.34, SE= 0.013, P,0.001), SK-BMD/UL-BMD (rp = 0.41,
SE= 0.013, P,0.001) and LL-BMD/UL-BMD (rp = 0.64,
SE= 0.010, P,0.001).
(DOCX)
Table S2 Characteristics of BMD measures and other anthro-
pometrical traits for participants of the ALSPAC and GEN-R
cohorts. (TBLH-BMD)= total-body less head BMD; (LL-
BMD)= lower limb BMD; (UL-BMD)=upper limb BMD; (SK-
BMD)= skull BMD; UNIT=unit of measurement; n= number of
subjects; SD= standard deviation of the mean value; (C-MEAN)= -
mean of trait measured for males and females; (F-MEAN)=mean of
trait measured in females; (M-MEAN)=mean of trait measured in
males. *Only 5299 subjects had skull BMD measurements.
(DOCX)
Table S3 Overall and population specific characteristics of
BMD measures and other anthropometric traits in Generation R.
(TBLH-BMD)= total-body less head BMD; (LL-BMD)= lower
limb BMD; (UL-BMD)= upper limb BMD; (SK-BMD)= skull
BMD; n= number of individuals; MEAN=mean value of each
trait; SD= standard deviation of the mean each trait; UNIT=unit
of measurement. Please note that these classifications are based on
self-reported ethnicity.
(DOCX)
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Table S4 Genome-wide associated TBLH-BMD variants.
(CHR)= chromosome number; (POS) = position in the genome
based on hg18; (EAF) = effect allele frequency; (b) = estimates of
effect size expressed as adjusted SD per copy of the effect allele
(EA); (SE) = standard error of b; (P) =P-value; (I2) =Cochran’s Q
statistic evaluating heterogeneity and (PHET) = evidence of hetero-
geneity. The SNP that showed the strongest evidence of
association at each locus is displayed in bold font.
(DOCX)
Table S5 Genome-wide associated LL-BMD variants.
(CHR)= chromosome number; (POS) = position in the genome
based on hg18; (EAF) = effect allele frequency; (b) = estimates of
effect size expressed as adjusted SD per copy of the effect allele
(EA); (SE) = standard error of b; (P) = P-value; (I2) =Cochran’s Q
statistic evaluating heterogeneity and (PHET) = evidence of hetero-
geneity. The SNP that showed the strongest evidence of
association at each locus is displayed in bold font.
(DOCX)
Table S6 Genome-wide associated UL-BMD variants.
(CHR)= chromosome number; (POS) = position in the genome
based on hg18; (EAF) = effect allele frequency; (b) = estimates of
effect size expressed as adjusted SD per copy of the effect allele
(EA); (SE) = standard error of b; (P) =P-value; (I2) =Cochran’s Q
statistic evaluating heterogeneity and (PHET) = evidence of hetero-
geneity. The SNP that showed the strongest evidence of
association at each locus is displayed in bold font.
(DOCX)
Table S7 Genome-wide associated SK-BMD variants.
(CHR)= chromosome number; (POS) = position in the genome
based on hg18; (EAF) = effect allele frequency; (b) = estimates of
effect size expressed as adjusted SD per copy of the effect allele
(EA); (SE) = standard error of b; (P) =P-value; (I2) =Cochran’s Q
statistic evaluating heterogeneity and (PHET) = evidence of hetero-
geneity. The SNP that showed the strongest evidence of
association at each locus is displayed in bold font.
(DOCX)
Table S8 Comparison of published BMD SNPs with results
from the total-body less head, lower limb, upper limb and skull
BMD GWAS. (LS-BMD)= lumbar spine BMD; (FN-BMD)= fe-
moral neck BMD; (F-BMD)= forearm BMD; (TBLH-BMD)= to-
tal-body less head BMD; (LL-BMD)= lower limb BMD; (UL-
BMD)=upper limb BMD; (SK-BMD)= skull BMD; (POSI-
TION) = location in the genome based on hg18; (GENE)= closest
gene; (PMID) = accession number of the publication in Pubmed
from which the summary statistics were obtained; (EA) = effect
allele; (EAF) = effect allele frequency; (b) = estimates of effect size
expressed as adjusted SD per copy of the effect allele (EA);
(SE) = standard error of b and (P) = pvalue; We failed to obtain
estimates for: rs9287237 (1q43, FMN2); rs7017914 (8q13.3,
XKR9); rs7851693 (9q34.11, FUBP3) and rs5934507 (Xp22.31,
FAM9B) as they were not imputed in the GEN-R dataset. Note for
rs9287237* (FMN2) and rs271170* (LOC285735/EYA4) the
summary statistics were obtained from a study performed by
Patenoster et. al. 2013 and represent the effect sizes and evidence of
association for these SNPs with volumetric trabecular (LS-BMD
column) and cortical BMD (FN-BMD column).
(DOCX)
Table S9 Sensitivity analysis comparing genome-wide signifi-
cant SNPs associated with bone mineral density measured at four
skeletal sites. (TBLH-BMD)= total-body less head BMD,
(LL-BMD)= lower limb BMD, (UL-BMD)= upper limb BMD,
(SK-BMD)= skull BMD. (MODEL 0) =GWAS meta-analysis
performed on age-, gender-, weight- or height-adjusted BMD,
(MODEL 1a) =GWAS meta-analysis performed on age-, gender-,
weight- and height-adjusted BMD, (MODEL 1b) =GWAS meta-
analysis performed on age-, gender-, weight- and height-adjusted
BMD measurements in individuals of European ancestry.
(GENE) = closest gene, (POS) = position in the genome based on
hg18, (EAF) = effect allele frequency, (b) = estimates of effect size
expressed as adjusted SD per copy of the effect allele (EA),
(SE) = standard error of b, (P) = pvalue, (I2) =Cochran’s Q statistic
evaluating heterogeneity, (PHET) = evidence of heterogeneity and
*Sample sizes used for SK-BMD genome-wide meta-analysis.
**Please note that PTHLH is also located at the 12p11.22 locus
containing KLHDC5, RSPO3 is also located at the 6q.22.32 locus
containing CENPW, FAM3C and CPED1 are also located at the
7q.31.31 locus containing WNT16, TNFRSF11B is also located at
the 8q.24.12 locus containing COLEC10, LGR4 is also located at
the 11p14.1 locus containing LIN7C and LRP5 is also located at
the 11q13.2 locus containing PPP6R3.
(DOCX)
Table S10 Top SNPs associated with bone mineral density of
the total-body less head, lower limb, upper limb and skull after
conditional meta-analysis. (TBLH-BMD)= total-body less head
BMD, (LL-BMD)= lower limb BMD, (UL-BMD)=upper limb
BMD, (SK-BMD)= skull BMD, (GENE)= closest gene, (POS) = -
position in the genome based on hg18, (EAF) = effect allele
frequency, (b) = estimates of effect size expressed as adjusted SD
per copy of the effect allele (EA), (SE) = standard error of b,
(P) = P-value, (I2) =Cochran’s Q statistic evaluating heterogeneity
and (PHET) = evidence of heterogeneity.
*Sample sizes used for SK-
BMD genome-wide meta-analysis. Locus specific multiple testing
correction thresholds as calculated by SNPSpD for SNPs in LD
are as follows: 1p36.12 (P#7.561025), 2q24.3 (P#4.761025),
6q22.32 (P#7.261025), 6q23.2 (P#8.961025), 7q31.31 (P#
1.261024), 8q24.12 (P#4.761025), 9q34.11 (P#9.461025),
11p14.1 (P#1.161024), 11q13.2 (P#6.361025), 12p11.22 (P#
4.161025), 13q14.11 (P#3.761025), 14q32.12 (P#4.561025)
and 18q21.33 (P#4.161025). **Please note that PTHLH is also
located at the 12p11.22 locus containing KLHDC5 and RSPO3 is
also located at the 6q.22.32 locus containing CENPW. FAM3C and
CPED1 are also located at the 7q.31.31 locus containing WNT16.
(DOCX)
Table S11 Lookup of selected primary and secondary BMD
SNPs in the publically released GEFOS GWAS of hip and spine
BMD, in addition to a comparison of the summary statistics across
each skeletal site before conditional analysis. (TBLH-BMD)= to-
tal-body less head BMD; (LL-BMD)= lower limb BMD; (UL-
BMD)= upper limb BMD; (SK-BMD)= skull BMD; (LS-
BMD)= lumbar spine BMD; (FN-BMD)= femoral neck BMD;
(GENE)= closest gene; (EA) = effect allele; (b) = estimates of effect
size expressed as adjusted SD per copy of the effect allele (EA);
(SE) = standard error of b and (P) = pvalue. Note – all the
summary statistics refer to those obtained prior to conditional
analysis and in the case of femoral neck or lumbar spine, the
results were obtained from the publically available data release
from the GEFOS consortium.
(DOCX)
Table S12 Published SNPs used for conditional meta-analyses.
(LS-BMD)= lumbar spine BMD; (FN-BMD)= femoral neck
BMD; (F-BMD)= forearm BMD; (TBLH-BMD)= total-body less
head BMD; (SK-BMD)= skull BMD; BMD; (TRABEC-
BMD)= volumetric trabecular BMD of the tibia; (CORT-
BMD)= volumetric cortical BMD of the tibia. (POSITION) = lo-
cation in the genome based on hg18; (GENE)= closest gene;
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(PMID) = accession number of the publication in Pubmed from
which the summary statistics were obtained; (b) = estimates of
effect size expressed as adjusted SD per copy of the effect allele;
(SE) = standard error of b and (P) = P-value. *Please note that
PTHLH is also located at the 12p11.22 locus containing KLHDC5,
RSPO3 is also located at the 6q.22.32 locus containing CENPW,
FAM3C and CPED1 are also located at the 7q.31.31 locus
containing WNT16, TNFRSF11B is also located at the 8q.24.12
locus containing COLEC10, LGR4 is also located at the 11p14.1
locus containing LIN7C and LRP5 is also located at the 11q13.2
locus containing PPP6R3. **The Generation R cohort did not
impute the published FUBP3 SNP (rs7851693) and therefore we
chose to condition on rs7030440, a SNP which was in high LD
(HapMap phase 2 release 22, CEU: r2 = 0.96) with the published
FUBP3 associated BMD variant. ***No previous BMD SNPs
found in 14q32.12 have been published.
(DOCX)
Table S13 Comparison of transcript levels between healthy and
osteoporotic women. Transcript log2 signal levels expressed from
genes 6250 Kb of rs754388 were compared between postmen-
opausal osteoporotic women with fracture and healthy controls
using students T-test. Transcripts with maximal log2 signal values
below 4 were excluded. (SD) = Standard deviation and (P) = P-
value.
(DOCX)
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